Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2012

View Archived Issues

Clinical results presented for the RTS,S/AS01 malaria vaccine

Novel pegylated camptothecin derivatives disclosed by Chinese researchers

Stanford University creates novel peptide therapeutics for leishmaniasis and trypanosomiasis

Pfizer reports topline results from phase III pregabalin trial in epilepsy

JCR's phase II/III stem cell trial completes enrollment

Xenetic reports phase I/IIa MS vaccine trial initiation in Russia

Incyte and Lilly present promising phase II data for baricitinib in rheumatoid arthritis

Novel 3D neuroblastoma-based in vitro culture model designed to investigate tauopathies

Researchers publish results of first-in-human trial of APR-246

Novel mGlu5 receptor modulators disclosed by Roche

New vaccines for birch pollen allergy presented by Teknologian Tutkimuskeskus

Santaris Pharma prepares novel antisense oligonucleotides

Bayer patents new TTK inhibitors

NeuroSearch designs new modulators of neurotransmission

CHMP recommends Exjade approval for non-transfusion-dependent thalassemia syndromes

Zytiga receives positive CHMP recommendation for castration-resistant prostate cancer

Brd1 gene knockout produces schizophrenia and depression phenotypes

Pluristem begins phase I/II trial of PLX cells in muscle injury

Amgen describes novel peptide agonist of the CaS receptor

Alexza Pharmaceuticals receives updated list of outstanding issues for Adasuve

Sobi files MAA to expand Kineret label

GlaxoSmithKline receives new FDA approval for Promacta

CFFT and Pfizer expand drug discovery collaboration

UCB begins phase III lacosamide study in Asia

FDA grants fast track status to OBI-1 for acquired hemophilia A

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...